The dilutive offering will pressure ANRO stock near-term, but the capital fully funds the Phase 3 program for ALTO-207 through key data readouts. Monitor the Phase 3 trial initiation and enrollment updates as the next catalysts. The lock-up agreement prevents insider selling for 60 days, which may limit post-offering downside.
Price Chart
Executive Summary
Alto Neuroscience entered into an underwriting agreement for a $100M public offering of 3,776,436 shares at $26.48 per share, with estimated net proceeds of ~$93.9M to fund accelerated Phase 3 development of ALTO-207 for treatment-resistant depression. The offering represents immediate dilution of ~10.8% to existing shareholders, though the capital extends the company's runway for its lead pipeline candidate.
Key Financial Metrics
Key Facts
- Offering of 3,776,436 shares of common stock at $26.48 per share
- Estimated net proceeds of ~$93.9M after underwriting discounts and commissions
- Proceeds to fund additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression
- Underwriters include BofA Securities, Stifel, William Blair, Robert W. Baird, JonesTrading, and H.C. Wainwright
- Closing expected July 14, 2026, subject to customary conditions
- 60-day lock-up agreements for directors, officers, and certain stockholders
Financial Impact
Immediate dilution of ~10.8% of pro forma shares outstanding; $93.9M net cash added to prior cash balance of ~$244.2M
Risk Factors
- Immediate EPS dilution from 10.8% share count increase
- Phase 3 trial failure risk for ALTO-207 in treatment-resistant depression
- Biotech market risk — capital raises in pre-revenue companies often meet post-announcement selling pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ANRO) — Batch item 1 | 0001104659-26-083274 |
| Document: tm2620328d1_8k.htm | 0001104659-26-083274 |
| Document: tm2620328d1_ex5-1.htm | 0001104659-26-083274 |
| Document: 0001104659-26-083274-index-headers.html | 0001104659-26-083274 |
| Document: 0001104659-26-083274-index.html | 0001104659-26-083274 |
| Document: 0001104659-26-083274.txt | 0001104659-26-083274 |
| 8-K Filing (ANRO) — Batch item 7 | 0001104659-26-083274 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | Institutional Cluster | $32.30 $34.25 | ▲ +6.04% | ▲ +8.00% | $23.35 (−27.71%) |
Jul 14, 2026 15w ago | 8-K | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.35 (+16.01%) |
Jul 14, 2026 15w ago | 424B5 | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $23.35 (+16.01%) |
Jul 13, 2026 15w ago | 8-K | $28.03 $27.54 | ▼ −1.75% | ▼ −0.96% | $23.35 (−16.70%) |
Jun 11, 2026 19w ago | Institutional Cluster | $21.47 $22.74 | ▲ +5.92% | ▲ +5.24% | $23.35 (+8.76%) |
May 29, 2026 21w ago | 3 | $19.80 $18.26 | ▼ −7.78% | ▼ −5.03% | $23.35 (+17.93%) |
May 28, 2026 21w ago | 8-K | $20.22 $18.85 | ▼ −6.78% | ▼ −6.73% | $23.35 (+15.48%) |
May 13, 2026 23w ago | 8-K | $22.85 $20.45 | ▼ −10.50% | ▼ −9.35% | $23.35 (+2.19%) |
Apr 21, 2026 27w ago | EFFECT | $25.59 $24.47 | ▼ −4.38% | ▼ −5.46% | $23.35 (−8.75%) |
Apr 10, 2026 28w ago | S-3 | $25.75 $27.33 | ▲ +6.14% | ▲ +2.84% | $23.35 (−9.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers